<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37142639</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>7270</StartPage><MedlinePgn>7270</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7270</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-34022-0</ELocationID><Abstract><AbstractText>This study identified trends in hydroxychloroquine (HCQ) prescription and retinopathy screening in patients with systemic lupus erythematosus (SLE) according to clinical practice guidelines to minimise the risk of HCQ retinopathy. We used data from patients diagnosed with SLE between 2004 and 2019 from the National Health Insurance Service in Korea. To assess trends of daily dose per actual body weight (ABW), we performed an interrupted time-series analysis and identified effects after revision of guidelines. Among 38,973 patients with SLE, 28,415 (72.9%) were prescribed HCQ from 2004 to 2019. The proportion of patients using HCQ among SLE patients was 63% in 2004 and increased to 76% in 2019. The median daily dose per ABW for HCQ users decreased from 5.88&#xa0;mg/kg in 2004 to 3.98&#xa0;mg/kg in 2019, and from 5.45&#xa0;mg/kg in 2005 to 4.17&#xa0;mg/kg in 2019 for HCQ new users. The annual implementation rate of screening tests among HCQ new users increased from 3.5% in 2006 to 22.5% in 2019. Study results indicated that HCQ dosing management was adequate based on the revised guidelines. Although the implementation rate of retinal screening has increased, it is necessary to enhance awareness of retinal screening in clinical settings.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Jae-Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Global Innovative Drugs and College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nam</LastName><ForeName>Dal Ri</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Global Innovative Drugs and College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Yoon-Kyoung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yu Jeong</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hanyang University Hospital, Seoul, 04763, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Sun-Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Global Innovative Drugs and College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea. jsyoung@cau.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012164" MajorTopicYN="Y">Retinal Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37142639</ArticleId><ArticleId IdType="pmc">PMC10160043</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-34022-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-34022-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanouriakis A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Eo D-R, et al. Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J. Korean Med. Sci. 2017;32:522&#x2013;527. doi: 10.3346/jkms.2017.32.3.522.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2017.32.3.522</ArticleId><ArticleId IdType="pmc">PMC5290114</ArticleId><ArticleId IdType="pubmed">28145658</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453&#x2013;1460. doi: 10.1001/jamaophthalmol.2014.3459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459</ArticleId><ArticleId IdType="pubmed">25275721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology (Oxford) 2016;55:957&#x2013;967. doi: 10.1093/rheumatology/kev357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev357</ArticleId><ArticleId IdType="pubmed">26428520</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen, C. Y. et al. Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: a nationwide population-based cohort study. Medicine (Baltimore)98, e15122. 10.1097/MD.0000000000015122 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6455786</ArticleId><ArticleId IdType="pubmed">30946384</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415&#x2013;422. doi: 10.1016/j.ophtha.2010.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2010.11.017</ArticleId><ArticleId IdType="pubmed">21292109</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Ophthalmology. 2016;123:1386&#x2013;1394. doi: 10.1016/j.ophtha.2016.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId><ArticleId IdType="pubmed">26992838</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco MA, et al. Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. Rheumatol. Int. 2017;37:1611&#x2013;1618. doi: 10.1007/s00296-017-3782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3782-6</ArticleId><ArticleId IdType="pmc">PMC5693716</ArticleId><ArticleId IdType="pubmed">28748425</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Jorge AM, Marmor MF, Zhang Y, Choi HK. Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. Clin. Rheumatol. 2018;37:1853&#x2013;1859. doi: 10.1007/s10067-018-4116-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4116-0</ArticleId><ArticleId IdType="pmc">PMC6402769</ArticleId><ArticleId IdType="pubmed">29696437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HK, Song SO, Noh J, Jeong IK, Lee BW. Data configuration and publication trends for the Korean national health insurance and health insurance review &amp; assessment database. Diabetes Metab. J. 2020;44:671&#x2013;678. doi: 10.4093/dmj.2020.0207.</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2020.0207</ArticleId><ArticleId IdType="pmc">PMC7643590</ArticleId><ArticleId IdType="pubmed">33115211</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol. Int. 2014;34:909&#x2013;917. doi: 10.1007/s00296-013-2915-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-013-2915-9</ArticleId><ArticleId IdType="pubmed">24322455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonnemann G, Duttlinger J, Hohmann D, Hickstein L, Reichel H. Timely referral to outpatient nephrology care slows progression and reduces treatment costs of chronic kidney diseases. Kidney Int. Rep. 2017;2:142&#x2013;151. doi: 10.1016/j.ekir.2016.09.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2016.09.062</ArticleId><ArticleId IdType="pmc">PMC5720523</ArticleId><ArticleId IdType="pubmed">29318212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 2002;27:299&#x2013;309. doi: 10.1046/j.1365-2710.2002.00430.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2710.2002.00430.x</ArticleId><ArticleId IdType="pubmed">12174032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EH, et al. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: A nationwide population-based study. Korean J. Int. Med. 2020;35:652&#x2013;661. doi: 10.3904/kjim.2018.303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2018.303</ArticleId><ArticleId IdType="pmc">PMC7214355</ArticleId><ArticleId IdType="pubmed">31212409</ArticleId></ArticleIdList></Reference><Reference><Citation>Murimi-Worstell IB, et al. Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States. J. Rheumatol. 2020 doi: 10.3899/jrheum.191187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.191187</ArticleId><ArticleId IdType="pubmed">32611669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernder A, et al. Quality of care predicts outcome in systemic lupus erythematosus: A cross-sectional analysis of a German long-term study (LuLa cohort) Lupus. 2020;29:136&#x2013;143. doi: 10.1177/0961203319896626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319896626</ArticleId><ArticleId IdType="pmc">PMC6993135</ArticleId><ArticleId IdType="pubmed">31992161</ArticleId></ArticleIdList></Reference><Reference><Citation>Langham J, et al. Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: A real-world observational retrospective cohort analysis. Rheumatol. Adv. Pract. 2021 doi: 10.1093/rap/rkab061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkab061</ArticleId><ArticleId IdType="pmc">PMC8452998</ArticleId><ArticleId IdType="pubmed">34557623</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum JT, et al. American college of rheumatology, American academy of dermatology, rheumatologic dermatology society, and American academy of ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthrit. Rheumatol. 2021;73:908&#x2013;911. doi: 10.1002/art.41683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41683</ArticleId><ArticleId IdType="pubmed">33559327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Food and Drug Safety. Hydroxychloroquine label information. https://nedrug.mfds.go.kr/searchDrug. Accessed 2023 March 24.</Citation></Reference><Reference><Citation>Osmani Z, et al. Hydroxychloroquine treatment in European patients with lupus erythematosus: Dosing, retinopathy screening and adherence. Lupus Sci. Med. 2021;8:e000478. doi: 10.1136/lupus-2021-000478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000478</ArticleId><ArticleId IdType="pmc">PMC8021889</ArticleId><ArticleId IdType="pubmed">33795484</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida-Brasil CC, et al. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann. Rheum. Dis. 2022;81:370&#x2013;378. doi: 10.1136/annrheumdis-2021-221295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221295</ArticleId><ArticleId IdType="pmc">PMC8862090</ArticleId><ArticleId IdType="pubmed">34911705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>